{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(1)"],"submitter":["Limbrick-Oldfield EH"],"pubmed_abstract":["<h4>Introduction</h4>Follicular lymphoma (FL) has a heterogeneous prognosis. Progression within 24 months of starting front-line therapy (POD24) is prognostic of overall survival (OS). Despite its prognostic value in early lines, the role of POD24 in relapsed/refractory (R/R) patients initiating later lines of therapy (LoTs) is unknown.<h4>Methods</h4>We analyzed the SCHOLAR-5 real-world cohort to investigate whether POD24 is prognostic in patients with R/R FL initiating ≥3rd LoT.<h4>Results</h4>Among the 128 SCHOLAR-5 patients, 34 patients experienced POD24. POD24 patients received their ≥3 LoT after a shorter time compared with non-POD24 patients (median 42.0 months [range: 8.8‒17.8] vs. 109.9 months [range: 29.6‒310.2]). Using a time-dependent multivariate Cox model, POD24 was predictiv"],"journal":["EJHaem"],"pagination":["e1104"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11800366"],"repository":["biostudies-literature"],"pubmed_title":["The prognostic value of POD24 in relapsed/refractory follicular lymphoma-A SCHOLAR-5 analysis."],"pmcid":["PMC11800366"],"pubmed_authors":["Palivela M","Gribben JG","Limbrick-Oldfield EH","Beygi S","Ray MD","Ghione P","Patel AR","Best T","Kanters S"],"additional_accession":[]},"is_claimable":false,"name":"The prognostic value of POD24 in relapsed/refractory follicular lymphoma-A SCHOLAR-5 analysis.","description":"<h4>Introduction</h4>Follicular lymphoma (FL) has a heterogeneous prognosis. Progression within 24 months of starting front-line therapy (POD24) is prognostic of overall survival (OS). Despite its prognostic value in early lines, the role of POD24 in relapsed/refractory (R/R) patients initiating later lines of therapy (LoTs) is unknown.<h4>Methods</h4>We analyzed the SCHOLAR-5 real-world cohort to investigate whether POD24 is prognostic in patients with R/R FL initiating ≥3rd LoT.<h4>Results</h4>Among the 128 SCHOLAR-5 patients, 34 patients experienced POD24. POD24 patients received their ≥3 LoT after a shorter time compared with non-POD24 patients (median 42.0 months [range: 8.8‒17.8] vs. 109.9 months [range: 29.6‒310.2]). Using a time-dependent multivariate Cox model, POD24 was predictiv","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2025-04-05T00:00:27.786Z","creation":"2025-04-05T00:00:27.786Z"},"accession":"S-EPMC11800366","cross_references":{"pubmed":["39917356"],"doi":["10.1002/jha2.1104"]}}